Vertex Pharmaceuticals Incorporated (FRA:VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 85.16B |
| Revenue (ttm) | 9.72B |
| Net Income (ttm) | 3.10B |
| Shares Out | n/a |
| EPS (ttm) | 11.98 |
| PE Ratio | 27.50 |
| Forward PE | 19.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 439 |
| Average Volume | 489 |
| Open | 330.95 |
| Previous Close | 329.20 |
| Day's Range | 330.95 - 336.80 |
| 52-Week Range | 312.65 - 489.20 |
| Beta | n/a |
| RSI | 33.46 |
| Earnings Date | Aug 4, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
1.95M Reasons To Be Bullish On Vertex Pharmaceuticals Stock
On August 7, a substantial insider purchase was made by BRUCE SACHS , Board Member at Vertex Pharmaceuticals (NASDAQ: VRTX), as per the latest SEC filing. What Happened: SACHS's recent move, as outli...
Meet Reshma Kewalramani who joins the list of 100 Most Powerful People in Business 2025 alongside Jensen Huang, Sundar Pichai, and others
Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most Powerful People in Business, ranking at 62. As the first Indian-origin woman to...
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District
The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average...
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ: VRTX) revealed 55 unusual trades. Delving into the...
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip
There's more good news than bad news for this big biotech stock.
Weakness In Vertex Stock Seen As Buying Opportunity
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings. See real-time price for VRTX stock here. On Monday, t...
Weakness In Vertex Stock Seen As Buying Opportunity
Vertex Pharmaceuticals Inc. VRTX stock is falling on Tuesday after the company's pain data overshadowed strong second-quarter earnings.
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday. The company's revenue came in at $2.97 billion versus estimat...
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Inspire Medical Systems, Inc. (NYSE: INSP) fell sharply in pre-market trading after the com...
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Vertex Pharmaceuticals stock falls as pain drug fails in phase 2
Vertex Pharmaceuticals (VRTX) falls premarket as VX-993 fails Phase 2 pain study endpoint.
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ETCompany ParticipantsCharles F.
Vertex Pharmaceuticals Incorporated 2025 Q2 - Results - Earnings Call Presentation
Vertex tops estimates on cystic fibrosis treatment strength, new products
Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.
Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings
The biotechnology company's stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.
Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report . Q2 Revenue: $2.97 billion versus estimat...
Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more
These are the stocks posting the largest moves in extended trading.
Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
Vertex to stop developing new painkiller as solo treatment after mid-stage study setback
Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo treatment after it failed to meet the main goal of a mid-stage trial.
Vertex Pharmaceuticals Non-GAAP EPS of $4.52 beats by $0.27, revenue of $2.96B beats by $50M
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-rangi...
Vertex Reports Second Quarter 2025 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 fina...